Kyverna Therapeutics, Inc. (KYTX) stock
KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.70−0.06 (-1.26%)
Close on Nov 17, 2026Market cap $290.66MP/E –Yield –
Kyverna Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
No gross margin figures for Kyverna Therapeutics
Kyverna Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?